No profile data available.
Legend Biotech Corporation (LEGN) is a healthcare company in the blood cancer treatment drugs industry, based in Somerset, United States, with about 3,200 full-time employees.
It reported revenue of $1.03 billion for fiscal year 2025, up 64.0% from fiscal year 2024, and net income of -$296.80 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $387.50 million, up 51.9% from a year before. United States of America was its largest region in fiscal year 2025, with 78% of revenue. Its market capitalization was $3.62 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
Legend Biotech reported $1.03 billion in revenue for fiscal year 2025, up 64.0% from $627.24 million in fiscal year 2024. In Q2 2026 revenue was $387.50 million.
United States of America: 78% of revenue by region in fiscal year 2025, followed by outside The United States of America (19%).
$3.62 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include BeOne Medicines AG (ONC), Genmab A/S (GMAB), Sellas Life Sciences Group, Inc. (SLS), Ascentage Pharma Group International (AAPG).